Jamael Hoosain, MD
Advanced Heart Failure and Transplant Cardiology · Philadelphia, PANPI 1689939712
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,946 of the $5,467 with a category attached, or 72.2%. 19 manufacturers reported payments, led by Abbott at 46.6% of the total. Reporting peaked in 2019 at $3,152 and has fallen 83.3% since, to $525 in 2025.
Across 111 payments — averaging $49.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Abiomed$801
- Pfizer$442
- Impulse Dynamics (USA) Inc.$295
- Actelion Pharmaceuticals US, Inc.$272
- Boston Scientific$184
- plus $928 from 13 others
What the payments were for
- Travel & lodging$1,07720%
- Food & beverage$3,94672%
- Education$4448%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 57 | $2,545 |
| Abiomed | 7 | $801 |
| Pfizer | 8 | $442 |
| Impulse Dynamics (USA) Inc. | 8 | $295 |
| Actelion Pharmaceuticals US, Inc. | 7 | $272 |
| Boston Scientific | 2 | $184 |
| Medtronic | 1 | $142 |
| Bayer | 2 | $129 |
| Boehringer Ingelheim | 1 | $105 |
| W. L. Gore & Associates, Inc. | 1 | $102 |
| United Therapeutics Corporation | 1 | $100 |
| Novartis | 5 | $98 |
| Minerva Surgical, Inc | 1 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Novo Nordisk | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Philips North America LLC | 1 | $26 |
| Merck | 1 | $26 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,467 in reported general payments places this provider in the 55th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
See all advanced heart failure and transplant cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 326 | $7,251,235 |
| OpsumitMacitentan | 33 | $410,679 |
| EliquisApixaban | 216 | $244,114 |
| JardianceEmpagliflozin | 92 | $73,183 |
| EntrestoSacubitril/Valsartan | 71 | $61,400 |
| XareltoRivaroxaban | 46 | $47,828 |
| FarxigaDapagliflozin Propanediol | 23 | $23,356 |
| OzempicSemaglutide | 16 | $13,381 |
| Sildenafil Citrate | 55 | $9,322 |
| Metoprolol Succinate | 261 | $5,261 |
| Mycophenolic AcidMycophenolate Sodium | 13 | $2,880 |
| Valsartan | 48 | $2,576 |
| Torsemide | 86 | $2,244 |
| Atorvastatin Calcium | 200 | $2,210 |
| Amiodarone Hcl | 47 | $2,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $442 | $7,495,349542 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $272 | $410,67933 claims |
| Boehringer IngelheimJardiance | $105 | $73,18392 claims |
| NovartisEntresto | $98 | $61,40071 claims |
| Novo NordiskOzempic | $40 | $13,38116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
Other advanced heart failure and transplant cardiology in Philadelphia
- Anjali VaidyaPhiladelphia$762K
- Jesus RamePhiladelphia$336K
- Ileana PinaPhiladelphia$284K
- Jeremy MazurekPhiladelphia$142K
- Lee GoldbergPhiladelphia$130K
- Anjali OwensPhiladelphia$109K
- Behnam BozorgniaPhiladelphia$107K
- Joyce WaldPhiladelphia$97K
- Paul MatherPhiladelphia$55K
- Hansie MathelierPhiladelphia$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.